US Point-of-Care Testing Infectious Disease Market, Forecast to 2022

CLIA Waived Molecular POCT, Coupled with Upcoming Diseases Like Sepsis, Lyme Disease, New Strains of Influenza—H1, H3, and H7, will Drive Growth
Share this:
Published: 5 Oct 2018

Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the outcome of diagnosis is time-bound, the test accuracy—sensitivity and specificity—plays a key role in determining the disease type, which is vital for delivering enhanced patient care and represents a major challenge. Point-of-care diagnostic testing (POCT) has the potential to rapidly identify the infectious diseases and provide actionable information to improve disease management, especially in resource-limited settings. The current challenges faced by the industry include efficiency of test accuracy, requirement for additional confirmatory test in laboratory, improper handling of patient samples, which may lead to errors and reimbursement cuts by Medicare and Medicaid. However, drivers such as technological innovation, expansion of CLIA-waived simple tests, and funding from research organization and NGOs have provided a strong impetus to the growth of the POCT market. With the synergistic effect of advanced technologies, such as chip-based PCR technique, fluid-phase immunoprecipitation assays, new multiplexing ecosystems, and smartphone-based POCT, the growth is anticipated to increase rapidly in the next 5 years.



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..